Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 18226 participants.
Also called NCT03473223
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 18,226 participants
- Sponsor
- Registry
-
NCT03473223 -
2017-000996-98
-
- Other papers using this trial's data
- ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial Infarction: Insights From the AEGIS-II Trial
- Apolipoprotein A-I infusions and cardiovascular outcomes in acute myocardial infarction according to baseline LDL-cholesterol levels: the AEGIS-II trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Croatia, Czechia, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hong Kong SAR China, Hungary, Israel, Italy, Japan, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, Peru, Poland, Portugal, Romania, Russia, Serbia, Singapore, Slovakia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Türkiye, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03473223. Randomized; quadruple masking; primary purpose prevention. Start 2018-03-21 (actual); primary completion 2023-02-16 (actual). Results posted on 2025-01-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
- Acronym
- AEGIS-II
- Condition
- Acute Coronary Syndrome
- Intervention (Biological)
- Apolipoprotein A-I [human] (apoA-I)
- Intervention (Other)
- Placebo
- Lead sponsor
- CSL Behring
Record details
- Record id
cardio:ct-nct03473223- Content hash
09e09775ea5c48486377f75161b13059a57364db27aa1c8c72518383e6f638bd